Clinically Studied Orally Administered Lavender Oil.
What is Lavela WS 1265?
- Steam-distilled oral lavender oil.
- Exclusive, safe and effective option
- Non-habit forming, non-sedating relief of occasional anxiety*
- Convenient, once daily dosing
An exclusive, clinically studied lavender oil.
Lavela WS 1265 is an exclusive lavender (Lavandula angustifolia) essential oil, known as Silexan™. Indicated for occasional anxiety, Lavela WS 1265 has been shown to promote relaxation and calm nervousness with safety and efficacy, as demonstrated in controlled trials published in peer-reviewed medical journals.*1ƺ
What makes Lavela WS 1265 unique?
Lavela WS 1265 is a powerful alternative to other available options.
Lavela WS 1265 offers relief without the side effects commonly seen in other options. Taken just once a day, this gentle, yet powerful, essential oil is non-habit-forming and well-tolerated. Clinical trials and a comparative analysis suggest that the effects of Lavela WS 1265 compare favorably to other options.*1ƻ
Recommendations for use:
Take one softgel daily with a full glass of water, or as recommended by your healthcare practitioner.
|Serving Size: 1 Softgel||Amount/Serving||%DV
Lavender Lavandula angustifolia) Oil (Silexan® brand)
canola oil, gelatin (capsule), glycerin, sorbitol, and annato extract color.
Product Specific Allergen Info:
This product does not contain:
- artificial flavoring
- dairy products
- ingredients of animal origin
This product contains natural ingredients; color variations are normal.
Several clinical studies show the benefit of Lavela WS 1265™ as compared to reference or placebo. The results are statistically significant and the response rate to treatment is high.
Efficacy of WS® 1265
Researchers Woelk and Schlfke conducted a multi-center, double-blind, randomized study of Lavela WS 1265 in comparison to a conventional agent for promoting relaxation.5 The Hamilton Anxiety Rating Scale (HAMA-total score) was used as the primary objective measurement to monitor changes in the level of tension and relaxation beginning at baseline through week 6 of the trial. Additional data were collected using the Self-Rating Anxiety Scale, Penn State Worry Questionnaire, and SF 36 Health Survey Questionnaire as well as Clinical Global Impressions.
A total of 77 female (76.6%) and male (23.4%) subjects 18-65 years of age were randomized into groups. Participants were eligible for the study if they met the inclusion criteria of a HAMA-total score of greater than 18 as well as a score equal to or greater than 2 on both anxious mood and tension items. Secondary objective outcome data were obtained from responder and remission rate comparisons made between the two treatment groups. In order for a participant to qualify as having a significant response to treatment they were required to have a reduction of at least 50% in the HAMA-total score during the six week trial. Remission was defined as a HAMA-total score of less than 10 points at the end of the six week study. The clinical results demonstrated that WS 1265 was comparable to the conventional approach. The HAMA-total score decreased by 45% in the WS 1265 group and decreased by 46% in the conventional group. At the conclusion of the six week intervention, 40% of the WS 1265 group and 27% of the conventional treatment group were determined to be in remission. The WS 1265 group had a response rate of 52.5% compared to only 40.5% taking the conventional option. Adverse effects in the WS 1265 group were uncommon and included nausea (5.2%), eructation (3.9%) and dyspepsia (2.6%).
Comparison to conventional options
Another study was performed to investigate the efficacy of WS 1265 in comparison to placebo in a primary care setting.13 In 27 general and psychiatric practices 221 adults reporting unspecified anxiety were randomized to receive 80 mg per day of WS 1265 or placebo for 10 weeks with office visits every 2 weeks. A baseline HAMA total score of ≥18 and a total score > 5 for the Pittsburgh Sleep Quality Index (PSQI) were required. The primary outcome measures were HAMA and PSQI total score decrease between baseline and week 10. Secondary efficacy measures included the Clinical Global Impressions scale, the Zung Self-rating Anxiety Scale, and the SF (Quality of Life) Health Survey Questionnaire. Subjects taking WS® 1265 showed a total score decrease by 16.0� 8.3 points (mean� SD, 59.3%) for the HAMA and by 5.5� 4.4 points (44.7%) for the PSQI compared to 9.5� 9.1 (35.4%) and 3.8� 4.1 points (30.9%) in the placebo group (P < 0.01 one-sided, intention to treat). WS 1265 was superior to placebo regarding the percentage of responders (76.9 vs. 49.1%, P< 0.001) and remitters (60.6 vs. 42.6%, P=0.009). Adverse events were uncommon and included dyspepsia (4.7% in the treatment group vs 1.8% in the placebo group) and eructation (3.7% in the treatment group and none in the placebo group).
Lavela WS 1265™ had a significant beneficial influence on quality and duration of sleep and improved general mental and physical health without causing any unwanted sedative effects.† Researchers concluded that WS 1265 was "both efficacious and safe" for the relief of occasional anxiety not otherwise specified.† It has a clinically demonstrable relaxing effect and was found to support restful sleep. †
Comparison to kava and conventional alternatives
Kava kava (Piper methysticum) was among better studied herbs for supporting relaxation, until concerns about liver toxicity prompted many companies to discontinue offering it. In a 6-week study, kava was found to produce a mean reduction of the HAMA score of 10 pointsᄾ whereas the mean reduction of that score from WS 1265 has ranged from 11.3 points (in a 6-week study)5 to 16 points (in a 10-week study).13 Other conventional approaches have mean HAMA reductions in the range of 11 to 15.3, suggesting comparable to superior efficacy of WS 1265 without the side effects associated with those options. 5ᄽ